The live biotherapeutic products and microbiome manufacturing market is projected to grow at a CAGR of 20% during 2022-2035, claims Roots Analysis

In recent years, the potential of microbiome-based leads for the treatment of a myriad disease indications has been widely recognized, presenting lucrative opportunities for drug developers and contract manufacturers alike.

London
Roots Analysis has announced the addition of the “Live Biotherapeutic Products ” report to its list of offerings.
Owing to the complex manufacturing processes, requirement of advanced GMP production facilities and the limited availability of inherent expertise, microbiome therapeutic developers are actively outsourcing certain manufacturing operations, in addition to expanding their in-house capabilities.

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen